CELLINK’s BIO X6 Platform: Pioneering the Future of 3D Bioprinting for Advanced Research and Drug Discovery

In a significant stride forward for the field of regenerative medicine and advanced scientific research, Boston-based CELLINK recently unveiled its groundbreaking BIO X6 bioprinting platform. This revolutionary system, equipped with an unprecedented six printheads, redefines the boundaries of what is possible in tissue engineering. Unlike any other system currently available on the market, the BIO X6 empowers researchers to combine a vastly greater array of materials, living cells, and specialized tools, enabling the creation of intricate and highly sophisticated biological constructs. CELLINK, a company synonymous with innovation in the bioprinting sector, specializes in the design and development of cutting-edge bioprinting technologies that facilitate the 3D printing of functional organs and various tissue types. These advanced constructs hold immense potential for diverse applications, ranging from critical pharmaceutical development and crucial disease modeling to groundbreaking advancements in cosmetics research. Furthermore, the company proudly offers a patent-pending bioink, meticulously engineered to foster the optimal growth and proliferation of human cells, replicating the conditions they would experience within their natural physiological environment. At its core, CELLINK’s overarching mission is to equip researchers globally with accessible and affordable bioprinting technology, thereby accelerating their research endeavors and unlocking new scientific discoveries. To delve deeper into this exciting development and the company’s vision, we had the privilege of speaking with CELLINK’s dynamic CEO and Co-Founder, Erik Gatenholm.

3DN: Can you tell us about yourself and your relationship with 3D printing technologies?

As the CEO and Co-founder of CELLINK, my journey with 3D printing technologies spans well over a decade, representing a profound passion and a clear vision for the future of medicine. From an early stage, I recognized the transformative potential of this market and knew it was an area I was destined to contribute to. The opportunity truly materialized when I met my brilliant co-founder, Hector Martinez. Together, we identified a significant and often overlooked gap in the market, specifically concerning the accessibility and universality of high-quality bioinks. At that time, researchers faced considerable challenges in acquiring suitable materials for their bioprinting experiments. This realization became the catalyst for our entrepreneurial venture. Alongside our dedicated founding team, we embarked on the ambitious task of commercializing the world’s first universal bioink. This innovation alone began to democratize access to bioprinting experiments. Building on this initial success, our vision expanded, leading us to not only continue developing advanced bioinks but also to begin manufacturing our own state-of-the-art 3D bioprinters and a comprehensive suite of other essential technologies specifically designed for the intricate demands of bioprinting. This holistic approach allowed us to provide researchers with complete solutions, fostering an environment where innovation could truly flourish without the limitations of fragmented tools or inaccessible materials.

3DN: What is CELLINK’s primary mission?

Our primary mission at CELLINK is fundamentally rooted in accessibility and empowerment: to provide researchers across the globe with affordable and robust bioprinting technology that can significantly further their vital research. As I previously touched upon, our initial insight into the market revealed a substantial void concerning readily available bioinks. This quickly evolved into a broader understanding that there was an incredible opportunity to truly democratize bioprinting technology itself. Before CELLINK, sophisticated bioprinting systems were often prohibitively expensive or complex, limiting their use to a select few well-funded institutions. We aimed to change that paradigm. By making these advanced tools more affordable and user-friendly, we could accelerate scientific progress on an unprecedented scale. The tangible impact of this mission is evident in our rapid growth and extensive reach; our sophisticated bioprinting systems are now operational in over 600 laboratories across more than 60 countries worldwide. This remarkable global presence has been achieved in a remarkably short period, driven by the dedication of our rapidly expanding team, which has grown to nearly 200 individuals in just three years. We firmly believe that continuous collaboration is key to progress, which is why we actively engage with leading researchers around the globe. These partnerships are instrumental in allowing us to continuously improve our existing technology and to develop innovative new products and solutions that directly address the evolving needs and challenges faced by the scientific community in their groundbreaking work. Our commitment extends beyond mere product provision; it’s about fostering a global ecosystem of innovation where every researcher, regardless of their institutional resources, has the tools to make profound scientific contributions.

3DN: Can you tell us more about your new bioprinting platform, the BIO X6?

The BIO X6 truly represents a monumental leap forward in the capabilities of bioprinting, designed specifically to push the boundaries of tissue engineering and complex biological modeling. Its defining feature is its revolutionary six-printhead configuration, which fundamentally differentiates it from any other system currently available in the market. This unique design liberates users from the limitations of conventional bioprinters, allowing them to combine a far greater diversity of materials, various cell types, and an extensive range of specialized tools simultaneously within a single printing process. With the BIO X6, researchers gain the unparalleled ability to integrate six or even more distinct cell types into their constructs. This multi-cellular integration is absolutely critical for accurately recreating the inherent complexity of advanced organ and tissue models, which are naturally composed of multiple cell populations interacting in intricate ways. The platform’s flexibility extends further: users can meticulously mix specific cell types within each individual printhead with a custom-tailored bioink. This personalized approach is paramount because it ensures that the cells are embedded within a biological environment precisely engineered to meet their unique needs for survival, proliferation, and differentiation. By providing this tailored microenvironment, the BIO X6 significantly enhances the chances of achieving the desired tissue architecture and functional properties, moving us closer to creating more physiologically relevant and accurate models for research, drug testing, and potentially, therapeutic applications. The precision and versatility offered by the BIO X6 are poised to unlock new avenues of research that were previously unimaginable, accelerating discovery in fields from disease understanding to regenerative medicine.

3DN: What is CELLINK currently working on and what are your future projects?

CELLINK is relentlessly focused on developing innovative and streamlined workflows tailored specifically for pharmaceutical companies and biologists worldwide. Our overarching goal is to empower these critical stakeholders to concentrate their invaluable efforts on their core mission: developing novel drugs and pioneering treatments that can effectively heal patients. To this end, CELLINK has strategically expanded its capabilities through two significant acquisitions over the past ten months. These acquired companies are instrumental players in the pharmaceutical development field, and their integration into the broader CELLINK family represents a crucial step forward in our mission to provide comprehensive solutions. This synergy allows us to offer a more complete ecosystem for drug discovery and validation, from bioprinting complex tissue models to advanced analytics. For our future projects, we recognize the imperative need for a deeper, more granular understanding of the biological behavior of the tissues we print. While the tissues we are capable of printing today already demonstrate immense potential, our focus is intensifying on elucidating the intricate cellular responses and long-term functionality of these constructs. We are actively collaborating with some of the world’s most distinguished scientists to meticulously apply these advanced 3D printed tissues to the rigorous drug development process. This involves using our printed models for more accurate toxicity screening, efficacy testing, and personalized medicine approaches. Our central focus remains steadfast: equipping biologists with the precise tools and comprehensive support they require to achieve groundbreaking success. Today, a significant part of that focus is centered on advancing 3D cell culturing. Our sophisticated systems and innovative reagents are meticulously engineered to facilitate a seamless transition for scientists from conventional, often less physiologically relevant, 2D cell culturing methods to the superior fidelity of printing 3D cultured tissues. These 3D models are inherently more realistic, offering a far better representation of in-vivo conditions, and consequently, perform significantly better in predictive assays. This profound shift from 2D to 3D culturing is not just an incremental improvement; it is poised to fundamentally revolutionize the pharmaceutical and biotechnology industries, leading to faster drug development, reduced animal testing, and more effective treatments for patients globally.

3DN: As a player in the 3D bioprinting industry, what is your vision of this segment of additive manufacturing?

We possess an immense passion for the 3D bioprinting field and are absolutely thrilled by its accelerated growth and the incredible advancements being made. However, it’s fair to say that CELLINK has always occupied a somewhat unique position, operating at the intriguing intersection of traditional additive manufacturing and the burgeoning life sciences. The broader additive manufacturing field, historically and predominantly, has concentrated on the precise printing and fabrication of non-living, inert materials – think metals, plastics, and ceramics for industrial applications. Our innovation, however, introduces an entirely new and profoundly complex component: human cells. By integrating living biological entities into the 3D printing paradigm, we are not merely expanding additive manufacturing; we are actively inventing a brand-new subcategory. This emerging domain is a powerful convergence of advanced additive manufacturing principles with sophisticated life science research and cutting-edge biotech fields. It is an incredibly exciting frontier to navigate, as it allows us to extend the capabilities of the additive manufacturing industry into an area where no one has truly ventured before – the creation of functional, living tissues and organ models. We are not just participating in this evolution; we are dedicated to leading the field, constantly pushing the boundaries of scientific discovery and technological development. This pioneering role comes with immense responsibility and unparalleled opportunities to contribute significantly to human health and scientific understanding. Our vision for this segment is one of exponential growth, continuous innovation, and ultimately, a future where 3D bioprinting becomes an indispensable tool for everything from fundamental biological research to personalized medicine and eventually, the production of transplantable tissues and organs, profoundly impacting countless lives.

For more comprehensive information on CELLINK’s innovative products and their groundbreaking research, you can find further details by visiting their official website HERE.

What are your thoughts on CELLINK’s ambitious future projects and the transformative potential of the BIO X6 bioprinting platform? We invite you to share your insights and comments below, or engage with our vibrant community on our Facebook and Twitter pages! Don’t miss out on the latest advancements and news in the dynamic world of 3D printing; sign up for our free weekly Newsletter and have all the essential updates delivered straight to your inbox!